Skip Navigation


JAC Advance Access originally published online on March 10, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/4/555    most recent
dkh157v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Richman, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richman, D. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 555-557
© 2004 The British Society for Antimicrobial Chemotherapy

Leading Article

Benefits and limitations of testing for resistance to HIV drugs

Douglas D. Richman*

Veterans Affairs San Diego Healthcare System and University of California San Diego, Departments of Pathology and Medicine, 0679, 9500 Gilman Drive, La Jolla, CA 92093–0679, USA

Since drug resistance was first described in HIV in 1989, great progress has been made in our understanding of its genetic basis and molecular mechanisms. Despite these advances and the introduction of many new antiretroviral drugs, resistance remains prevalent. The types of drug resistance tests and their relative advantages and disadvantages are reviewed. How and when these tests should be used to inform HIV clinical practice and their place in anti-HIV drug development are considered.

Keywords: antiretroviral drugs, HIV drug resistance, resistance testing

* Tel: +1-858-552-7439; Fax: +1-858-552-7445; E-mail: drichman{at}ucsd.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
D. Hoffmann, J. Seebach, A. Cosma, F. D. Goebel, K. Strimmer, H. M. Schatzl, and V. Erfle
Therapeutic vaccination reduces HIV sequence variability
FASEB J, February 1, 2008; 22(2): 437 - 444.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Martinez-Picado, T. Wrin, S. D. W. Frost, B. Clotet, L. Ruiz, A. J. L. Brown, C. J. Petropoulos, and N. T. Parkin
Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1
J. Virol., May 15, 2005; 79(10): 5907 - 5913.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. Martinez-Picado, K. Morales-Lopetegi, C. Villena, C. Gutierrez, N. Izquierdo, S. Marfil, B. Clotet, and L. Ruiz
Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification
J. Clin. Microbiol., January 1, 2005; 43(1): 436 - 438.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.